Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The report covers the month of April 2025, specifically detailing share repurchases executed on April 24, 2025. The filing serves as a disclosure of a non-discretionary buyback agreement entered into with Citigroup Global Markets Limited on February 24, 2025.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. No revenue, profit, cash flow, or debt metrics are provided in this specific document.
- Shares Purchased (April 24, 2025): 824,200 ordinary shares.
- Price Range (GBp): Lowest 1,373.00p; Highest 1,393.00p.
- Volume-Weighted Average Price (GBp): 1,385.89p.
- Cumulative Buyback (Since Feb 24, 2025): 32,836,252 ordinary shares.
- Treasury Shares Held: 201,906,555 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,113,331,903 ordinary shares.
- Total Voting Rights: 4,113,331,903.
Material Changes
The filing details a reduction in the number of shares in issue due to the acquisition of treasury shares. The specific transaction on April 24, 2025, reduced the outstanding share count by 824,200 shares. The filing does not provide comparative financial data against prior periods as it is a transactional report rather than a financial statement.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk factors" section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the total number of shares in issue (4,113,331,903) for calculating ownership percentages under FCA Disclosure Guidance and Transparency Rules.
- Confirm the status of the non-discretionary buyback agreement with Citigroup Global Markets Limited initiated on February 24, 2025.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for detailed risk factors referenced in the cautionary statement.
- Monitor future 6-K filings for updates on the remaining capacity of the current buyback programme.